Jacobs Levy Equity Management, Inc Protagonist Therapeutics, Inc Transaction History
Jacobs Levy Equity Management, Inc
- $25.8 Billion
- Q4 2024
A detailed history of Jacobs Levy Equity Management, Inc transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 128,654 shares of PTGX stock, worth $4.98 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
128,654
Previous 128,654
-0.0%
Holding current value
$4.98 Million
Previous $5.78 Million
14.1%
% of portfolio
0.02%
Previous 0.02%
Shares
15 transactions
Others Institutions Holding PTGX
# of Institutions
254Shares Held
58.9MCall Options Held
189KPut Options Held
191K-
Farallon Capital Management LLC San Francisco, CA5.93MShares$229 Million1.22% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$223 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.5MShares$213 Million3.46% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.22MShares$163 Million0.0% of portfolio
-
State Street Corp Boston, MA3.33MShares$129 Million0.01% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $1.9B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...